lot like anoth strong print
believ thermo fisher result speak organ
growth broad base across end market busi geographi addit
compani continu show momentum new product innov
believ see signal custom valu proposit allow take
share wallet market notabl thermo fisher post mid-teen growth
biopharma repres acceler recent trend believ
perform function continu share gain custom well
compani differenti portfolio across biopharma servic bioproduct
geograph standpoint thermo fisher leverag scale china deliv greater
growth note share gain encourag trend custom despit
trade rhetor growth broad base quarter highlight
thermo fisher deliv good growth compani bioproduct
clinic trial logist recent acquir patheon fei co busi
addit strength research safeti market channel help drive
organ growth rate lab product servic segment thermo fisher
channel choic custom overal stack result versu peer
think undeni thermo fisher take advantag favor end
market condit grow market share across number busi
given posit end market condit thermo fisher portfolio posit
would surpris compani outperform newli rais target
posit ep forecast high end
compani rang notabl compani rais organ growth
guidanc leverag around thermo fisher room deploy free cash
flow beyond activ alreadi announc would drive upsid forecast
believ strength thermo fisher result valid advantag
compani busi strategi result increas convict
thesi overweight rate rais pt
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight thermo fisher market leader
across divers portfolio life scienc tool
diagnost impress global reach across
custom class end market compani
consist track record organ growth capit
deploy manag execut
recommend share core hold exposur
innov healthcar
see upsid thermo fisher target
capit deploy better result
life acquisit upsid case reflect
upsid ebitda billion
thermo fisher exposur econom activ
end market could impact growth
downsid case reflect downsid
ebitda billion
believ thermo fisher result speak organ
growth broad base across end market busi geographi addit
compani continu show momentum new product innov believ
see signal custom valu proposit allow take share
wallet market notabl thermo fisher post mid-teen growth biopharma
repres acceler recent trend believ perform function
continu share gain custom well compani differenti portfolio
across biopharma servic bioproduct geograph standpoint thermo
fisher leverag scale china deliv greater growth note share gain
encourag trend custom despit trade rhetor growth broad
base quarter highlight thermo fisher deliv good growth
compani bioproduct clinic trial logist recent acquir patheon
fei co busi addit strength research safeti market channel
help drive organ growth rate lab product servic segment
thermo fisher channel choic custom overal stack result versu
peer think undeni thermo fisher take advantag favor end
market condit grow market share across number busi
given posit end market condit thermo fisher portfolio posit
would surpris compani outperform newli rais target
posit ep forecast high end compani rang
notabl compani rais organ growth guidanc
leverag around thermo fisher room deploy free cash flow beyond activ
alreadi announc would drive upsid forecast believ
strength thermo fisher result valid advantag compani busi
strategi result increas convict thesi overweight
better quarter free cash flow gener rais price target
price target repres ebitda forecast
billion prior price target also repres ebitda forecast
billion though compani lower net debt balanc quarter
gener drive equiti valu valuat higher
better quarterli result thermo fisher rais guidanc account
strong oper perform off-set less favor fx believ continu
conserv shown chart compani forecast revenu
billion low end repres
total revenu growth vs previous includ acquir
month patheon fx tailwind embed guidanc lower
forecast given result base trail fx methodolog
note fx becom headwind earn roughli top
line posit organ growth rate guidanc call midpoint
previou guidanc macro environ continu posit
believ rais outlook could still prove conserv
ep project rang y/i
midpoint versu previou rang rel prior guidanc
increas ep due tailwind organ trend increas tax
partial off-set ep headwind headwind tariff off-set
benefit account better organ outlook keep mind thermo
fisher guidanc includ capit deploy beyond alreadi announc
activ previous includ buy-back later complet
repurchas juli note gatan acquisit previous
expect close year end dont think impact current forecast pleas
see report gatan tuck-in deal slot nice fei
line thermo fisher anticip tax rate share
outstand interest expens
expect focu confer call relat thermo fisher
bioproduct busi appear post healthi growth
quarter notabl appear healthi trend bioproduct continu
third consecut quarter manag optimist long-term driver
bioproduct market believ custom valu proposit posit compani
well specif confer call ceo marc casper note mid-teen growth
pharma biotech feel good saw strength across busi
serv custom base rang bioproduct excel
chrome/mass spec clinic trial logist research safeti channel saw
strength across board consum product chromatographi instrument
mass spectrometri instrument good quarter think realli reflect uniqu
custom valu proposit uniqu posit drive
custom innov product
addit patheon perform well comp get favor head
year end remind impact hurrican maria caus patheon manati site
offlin period time thermo fisher three site island
puerto rico largest patheon site manati puerto rico base disclosur
patheon prior acquisit believ facil repres roughli
patheon manufactur footprint squar feet thermo fisher note site
gener roughli million revenu annual size impact
million facil locat north coast puerto rico total
compani employe island importantli margin thermo fisher
easier comparison due cost associ get site
oper
among life scienc tool peer believ thermo fisher uniqu capabl serv
biopharma end market under-appreci serv long-term
differenti growth driver compani altogeth biopharma end market
repres around thermo fisher revenu grown least m-hsd
compani foundat start research capabl channel busi
consolid histor driven growth thermo fisher aggreg client
wallet thermo fisher capabl product qa/qc continu perform well
global access therapeut drive demand liquid chromatographi beyond
thermo fisher uniqu capabl repres around revenu includ
bioproduct contract drug manufactur patheon clinic trial logist
see sustain long-term growth driver hsd-low-teen segment
believ long-term structur tailwind support visibl import growth
driver thermo fisher
thermo fisher uniqu biopharma exposur repres revenu mm
ttm result thru trial total total total biopharma total fisher biopharma contribut organ growthrevsbioproductionorgan growthrevsclin trial logisticsorgan growth barclay thermo fisher scientif inc
thermo fisher continu activ capit deploy believ
compani continu flexibl pursu larger start thermo
fisher acquir integenx march tuck-in deal area rapid forens
quarter compani announc acquisit gatan expect close year-
end return million sharehold dividend addit
compani note repurchas million share juli
compani activ highlight acquisit patheon close
lead global provid high-qual drug develop deliveri solut
biopharma market addit patheon acquisit thermo fisher activ
share repurchas complet number tuck-in acquisit includ finess
solut informat reflect compani complet acquisit
affymetrix march fei co septemb largest
transact compani histori thermo fisher complet billion capit
deploy call ceo casper note thermo fisher substanti
flexibl addit attract opportun present term
free cash flow project thermo fisher gener billion estim
thermo fisher end quarter net debt ttm ebitda near-term capit
deploy focus de-lever
net debt ttm ftm ebitda
june thermo fisher announc million acquisit gatan
subsidiari roper cover barclay analyst julian mitchel view
acquisit quintessenti tuck-in deal thermo fisher allow
compani streamlin fei oper manufactur develop
electron microscop modestli accret compani gatan
manufactur instrument softwar primarili use input
process develop electron microscop thermo fisher fei co market
leader electron microscopi major custom gatan
chanc catch thermo fisher announc appear
real opportun drive synergi across fei gatan given vertic integr
asset acquisit small revenu perspect
forecast believ earn contribut given
healthi margin thermo fisher uniqu posit gener integr
save thermo fisher appear natur home asset like abl
gener synergi hand competitor would abl achiev
deal aim provid cost advantag bring gatan technolog hous
debt ttm ebitdanet debt ntm ebitda barclay thermo fisher scientif inc
though also see potenti advantag time innov driven better
coordin activ context synergi wouldnt
surpris thermo fisher pay multipl ebitda ultim level
depend synergi deal expect close end
fund cash view deal anoth exampl highli strateg
acquisit thermo fisher compani continu lot
opportun ahead consolid industri
patheon clearli excit around acquisit believ
signific opportun take share win busi improv
profit asset remind billion acquisit patheon close
end august part lab product servic divis
acquisit make thermo fisher one market leader
contract drug
manufactur own patheon thermo fisher believ remov element
complex suppli chain biopharma custom mani biopharma
sponsor thermo fisher largest supplier spend weve seen
cro industri industri pressur sponsor led consolid number
trust supplier choos work similarli small mid-siz biotech
compani dont capabl manufactur api drug
thermo fisher see natur cross-sel opportun compani clinic
trial logist busi given thermo fisher scale biopharma servic like
biopharma sponsor alreadi work compani clinic
trial logist patheon provid logic hand-ov clinic trial logist busi
drug manufactur thermo fisher provid pack ship servic
trial lot risk handoff clinic trial work
thermo fisher believ
industri consolid around time
addit custom also need cold chain servic thermo fisher provid
charg real value-ad servic custom thermo fisher
intend keep ad capit select franchis time continu
strategi patheon pursu stand-alon entiti
thermo fisher note patheon track ahead deal model term
integr deal accret remind thermo fisher guid investor
year accret million ebit cost revenu synergi
year term revenu synergi million year million
ebit thermo fisher note alreadi receiv inbound request cross-
sell clinic trial logist addit thermo fisher brand credibl
custom make natur partner outsourc work aggreg
share compani see pipelin small molecul biotech
choic outsourc thermo fisher count
signific amount chang outsourc penetr could repres
upsid term cost synergi million year beyond natur area
opportun public compani cost duplic administr area procur
better util manufactur footprint would provid great deal earn
leverag thermo fisher see lot under-capac site own patheon
combin factor expect push margin mid-teen
compani averag time
call thermo fisher provid updat deal discuss
potenti custom ceo mark casper ad integr go realli well
custom feedback extraordinarili posit combin also
leverag relationship trust compani built time
posit term revenu synergi clearli see lot
interest momentum pipelin win cadenc busi
win today show revenu month affect short
term affect long-term growth prospect busi win
show clinic trial busi much shorter-cycl busi
clearli posit feel good go great
abl rais outlook busi last quarter
fei co believ thermo fisher acquisit fei co fit well compani
 strategi re-emphas call fei co bring market lead
platform electron microscopi microscop compani believ em
platform complement portfolio mass spectrometri certain applic
specif highlight protein identif character thermo
fisher also highlight intend drive adopt fei technolog
biopharma market compani differenti product portfolio c-level
relationship help extend fei co reach thermo fisher impress fei
manufactur facil brno czech republ plan leverag site notabl
first month ownership thermo fisher note accret
compani forecast remind fei annual
count toward organ growth organ growth electron microscopi
line compani averag
revenu billion came better estim billion
grew y/i driven mostli better organ growth higher better
 higher well essenti line fx organ growth
y/i better forecast guidanc sell day
chang y/i earlier versu may modest tailwind
entir coverag patheon ad lp segment growth impli revenu
contribut million fx tailwind revenu growth versu model
quarterli revenu mm total organ growth
store revenu growth segment
revenu contribut segment
non-gaap ep increas y/i came better
estim street compani tax rate
expect serv headwind ep versu model oper incom
primari driver core beat came better expect
non-gaap ep growth
adjust oper incom million came forecast
million grew y/i oper margin declin y/i
came expect back margin dilut
patheon benefit fx organ margin improv
quarter gross margin higher expect wherea sg
came higher expect revenu like mix
driven expens revenu par expect
adj oper incom mm growth
improv oper margin y/i
industri end market commentari solid importantli compani saw
continu strength biopharma end market mid-teen growth y/i
confer call manag elabor trend experienc market
academ govern end market grew high-singl digit quarter
benefit broad strength geograph thermo fisher see flow
fund healthi nih budget healthcar clinic grew mid-singl
digit benefit broad-bas strength thermo fisher achiev mid-teen
growth biopharma repres modest acceler recent trend strength
driven solid perform across compani busi compani
highlight bioproduct chromatography/mass spectrometri clinic trial logist
research safeti end market channel compani benefit healthi
market environ well share gain due unmatch product breadth notabl
trend industri end market remain solid growth mid-singl digit
compani deliv solid perform across chromatography/mass
spectrometri chemic analysi electron microscopi despit difficult comparison
manag commentari quarter
life scienc solut total organ growth
estim life scienc solut revenu came expect billion
increas y/i stronger organ growth drove revenu beat
revenu increas y/i versu estim remind follow
hurrican inventori destock issu thermo fisher bioproduct
busi sinc return strength quarter currenc roughli
tailwind growth line estim tailwind segment oper incom
million quarter increas y/i adjust oper margin
y/i
scienc growth particularli strong led growthexcel growthstrong growthmor mutedmodest growthstrong growthstrong growthveri growthbiosciencesstrong demandparticularli strong growthstrong growthstrong growthstrong growthveri growthnext sequencingstrong growthteen growthl growthexcel growthstrong demandstrong growthveri growthet analysi growthstrong demandveri growthanalyt appliedcontinu core weaknessindustri soft appli well lsd overallindustri continu weaknessgrew lsd appli strong order industrialgrew compani averag appli safeti channel industrialgrew compani averag appli return growth chemicalmsd growth good china growthmsd growthhsd growthmsd growthmass spechsd growth growth strong perform strong growthstrong growthstrong growthstrong growthstrong growthveri growthchromatographystrong growthhsd growth growth strong perform strong growthstrong growthstrong growthstrong growthstrong growthveri growthfei companystrong oper executionexcel oper performancedouble-digit growthstrong growthstrong growthveri growthspecialti dx clinic dxsolid growth across segmentsimmuno-dx similar trend good growth immuno transplant dxsimilar trend lsd strength clinic similar trend lsd strength clinic transplant particularli stronglsd growth transplant immunodiagnosticslsd strong season busi clinic transplant dxlsd particularli strong healthcar channelmsd transplant clinic diagnost channellab product govtlsd growthlsd growth grew slightli lsd growthlsd growthlsd growthmsd growth europ chinahsd growthmsd growthhsd growthpharma biotechhsd growthldd growthhsd growthhsd growthmsd growthmsd growthmid-teen growthbiopharma servicesveri strong growth growth littl slower particularli strong strong perform unfavor mix biopharma servicesunfavor mix biopharma servicesunfavor mix biopharma servicesgrow wellstrong growthstrong growth barclay thermo fisher scientif inc
analyt instrument total organ
instrument million stronger
expect revenu increas y/i organ currenc
tailwind quarter line estim tailwind sequenti organ
growth isnt surpris given outsiz growth thermo
fisher recent post fei co includ organ growth calcul
third full quarter close septemb organ growth fei co
line compani averag thermo fisher optimist fei co
acquisit look confer call detail integr tailwind
cycl acquisit includ integenx contribut
acquir growth quarter approxim segment oper incom
increas y/i million oper margin y/i
specialti diagnost organ organ growth
estim specialti diagnost result solid organ revenu
expect y/i currenc tailwind quarter line
estim tailwind report revenu improv adjust oper incom
increas y/i million oper margin flat y/i
laboratori product servic organ organ
growth estim laboratori product servic segment revenu came
expect quarter total revenu increas y/i organ revenu
increas acquisit patheon contribut segment revenu growth
versu estim commentari around patheon transact
posit look confer call detail statu integr
currenc currenc tailwind line estim tailwind
adjust ebit increas y/i million oper margin
declin y/i follow larg clinic trial cancel novemb
affect compani biopharma servic busi segment rev
busi return strength
geograph commentari strong highlight growth china
despit difficult comparison demand asia-pacif continu low-teen growth
highlight strength china thermo fisher remain optimist china
market despit rhetor around trade custom behavior region remain
encourag ceo casper note compani saw broad end market strength
region thermo fisher continu believ industri lead scale breadth
allow compani differenti region compani deliv mid-
singl digit growth north america high-singl digit growth europ rest
world grew low-teen repres acceler thermo
fisher continu priorit distribut e-commerc area invest
flow oper strong billion adjust net incom
capital-expenditure million repres revenu y/i thermo fisher
deploy million dividend sharehold manag repurchas
share follow august acquisit patheon recent announc acquisit
gatan estim thermo fisher end quarter net debt ttm ebitda
near-term capit deploy focus de-lever said believ
compani flexibl pursu acquisit modest repurchas
opportun present
cffo compon trend cffo free capital-expenditure mm
growthldd growthlow-teensldd growthldd growthhsd growthldd growthlow-teensmid-teenslow-teenschinahigh-teensmid-teenshigh-teensstrong americamsd growthlsd growthlsd growthlsd growthlsd growthhsd growthlsd growthmsd growtheuropemsd growthlsd growthlsd growthmsd growthmsd growthlsd growthmsd growthmsd growthmsd growthhsd growthrowhsd declinemsd declinelsd declinelsd declineflatflatmsd growthlow-teensmsd flowcffo net incom barclay thermo fisher scientif inc
thermo fisher mm except ep reportedincom growth profit ebitda ebit pre-tax pre-tax tax net net researchprior yearprior quarter barclay thermo fisher scientif inc
estestestestestestestestestestincom statement growth growth growth organ adj product product product revenu inc servic servic gross margin inc sg stock comp total sg product margin oper incom margin improv w/ improv annual bs annual bs debt item expens pre-tax tax benefit net averag sharesbas ep continu opsbas adj adj full-year barclay thermo fisher scientif inc
thermo fisher statement flow
estestestestestestestestesteststat activitiesnet discontinu dispos discontinu continu defer incom gain sale stock-bas interest expens convert benefit stock-bas comp charg sale non-cash expens work capitalaccount retir chang work cash provid continu cash use discontinu oper growth net activitiesacquisit net cash growth sale available-for-sal sale sale retir note increas restrict deriv invest activ use discontinu invest cash use invest activitiesnet proce issuanc long-term commerci paper convert long-term short-term note per proce issuanc proce issuanc employe benefit stock-compens financ activ cash provid financ rate effect equival equival growth adj net debt ttm barclay thermo fisher scientif inc
estestestestestestestestestestbal sheet asset cash receiv less allow tax current current less accumul intang asset payrol employe incom accru current incom long-term convert debt sharehold liabil barclay thermo fisher scientif inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
